News dal mondo

31

Lug

FDA unveils FY 2027 user fee rates

The US Food and Drug Administration (FDA) has published its user fee rates for FY 2027 across its prescription drug, generic drug, biosimilar, medical device, and over-the-counter drug programs. The rates are calculated by factoring in the agency’s resources against the number of applications it expects to receive over the next fiscal cycle based on historical trends...[US FDA - Federal Register]

21

Ago

EDQM - Update to the guidance for electronic submissions of CEP applications

The European Directorate for the Quality of Medicines & HealthCare (EDQM) has updated the guidance PA/PH/CEP...

14

Ago

FDA’s GDUFA IV commitment letter supports onshoring of generic drug manufacturing

The agency wants to increase the fee starting in fiscal 2028 for all foreign API, finished dosage form,...

11

Ago

UE approva acquisto di Recordati da parte di GBL e CVC

La Commissione europea ha approvato, ai sensi del Regolamento UE sulle concentrazioni,...